C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!

Pharma Press Releases

Keep up to date with the latest technological developments happening across the Pharmaceutical industry. Our press releases can help you boost your online reach and exposure worldwide. Our Press releases provides information on the latest research in pharma.

Moderna Receives Full U.S. FDA Approval for COVID-19 Vaccine Spikevax

Monday, January 31, 2022

Moderna Inc a biotechnology company pioneering messenger RNA mRNA therapeutics and vaccines today announced the US Food and Drug Administration FDA has approved the Biologics License Application BLA for SPIKEVAX COVID Vaccine mRNA to prevent COVID in...

U.S. FDA Approves New Label Update for CAR T-Cell Therapy Yescarta® Showing Prophylactic Steroid Use Improves Management of Cytokine Release Syndrome

Monday, January 31, 2022

Kite a Gilead Company today announced the US Food and Drug Administration FDA has approved an update to the prescribing information for Yescarta axicabtagene ciloleucel to include use of prophylactic corticosteroids across all approved indications Ye...

FDA approves Roche’s Vabysmo, the first bispecific antibody for the eye, to treat two leading causes of vision loss

Monday, January 31, 2022

Roche announced that the US Food and Drug Administration FDA has approved Vabysmo faricimabsvoa for the treatment of neovascular or wet agerelated macular degeneration nAMD and diabetic macular edema DME Neovascular AMD and DME are two leading causes...

Eppendorf expands its portfolio to address customers’ separation needs

Monday, January 31, 2022

Eppendorf expanded its centrifuge offering with the acquisition of the centrifugation business of the Japanese company Koki Holdings Co Ltd whose products are marketed globally under the brand name Himac in The introduction of the portfolio under th...

Construction works launch at new fill finish facility in Morocco

Saturday, January 29, 2022

Global contract development and manufacturing organisation CDMO Recipharm in charge of shaping the new entity SENSYO Pharmatech has attended a ceremony to recognise the launch of construction works at its new fill finish factory in Morocco The ceremo...

Calliditas Therapeutics Announces Commercial Availability and Initial Sales of TARPEYO™

Friday, January 28, 2022

Calliditas Therapeutics AB today announced the commercial availability and initial sales of TARPEYO budesonide the first and only FDA approved treatment for IgA nephropathy indicated for reduction of proteinuria in adults with primary IgA nephropathy...

Atai Life Sciences Launches Invyxis to Accelerate Discovery of Next-Generation Mental Health Treatments

Thursday, January 27, 2022

Atai Life Sciences NV a clinicalstage biopharmaceutical company aiming to transform the treatment of mental health disorders today launched Invyxis a new wholly owned platform company committed to developing new chemical entities NCEs and to further...

NeuroSense Therapeutics Extends ALS Biomarker Collaboration with Massachusetts General Hospital

Thursday, January 27, 2022

NeuroSense Therapeutics Ltd a company developing treatments for neurodegenerative diseases announced today the initiation of the third stage of a collaborative biomarker study with Massachusetts General Hospital MGH The extension of this collaborativ...

Ocugen, Inc. Signs Letter of Intent to Acquire Vaccine Manufacturing, R&D Hub in Ontario, Canada

Thursday, January 27, 2022

Ocugen Inc a biopharmaceutical company focused on discovering developing and commercializing breakthrough gene therapies and vaccines announced that it has signed a nonbinding letter of intent LOI with Liminal BioSciences Inc a Canadian public compan...

ALX Oncology Receives U.S. FDA Orphan Drug Designation for Evorpacept for the Treatment of Patients with Gastric Cancer and Gastroesophageal Junction Cancer

Thursday, January 27, 2022

ALX Oncology Holdings Inc ALX Oncology a clinicalstage immunooncology company developing therapies that block the CD checkpoint pathway today announced that the US Food and Drug Administration FDA granted orphan drug designation ODD to evorpacept a n...